Dividends & Buybacks ·
Gossamer Bio, Inc. stockholders approved several proposals at a special meeting on July 14, 2026
GOSSGossamer Bio, Inc.
Gossamer Bio, Inc. stockholders approved several proposals at a special meeting on July 14, 2026. Key approvals include an amendment to the 2019 Incentive Award Plan and a charter amendment to increase authorized common stock from 700,000,000 to 4,000,000,000 shares. This increase supports future issuances related to $72.0 million in New Convertible Notes and the exercise of 135,789,000 purchase warrants. Additionally, stockholders approved a series of charter amendments to implement a reverse stock split and a proportionate reduction in authorized shares. Gossamer Bio, Inc. is a biotechnology company.